• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Inhibition of PC-3 prostate cancer cell growth in vitro using both antisense oligonucleotides and taxol.

作者信息

Rubenstein Marvin, Slobodskoy Leonid, Mirochnik Yelena, Guinan Patrick

机构信息

Division of Cellular Biology, Hektoen Institute for Medical Research, Chicago, IL, USA.

出版信息

Med Oncol. 2003;20(1):29-35. doi: 10.1385/MO:20:1:29.

DOI:10.1385/MO:20:1:29
PMID:12665682
Abstract

Antisense oligonucleotides (oligos) directed against mRNA-encoding transforming growth factor-alpha (TGF-alpha) and the epidermal growth factor receptor (EGFR) have demonstrated in vitro and in vivo efficacy against prostate cancer tumor models. However, many therapeutic agents have increased effectiveness when given in combination with other more established agents. We evaluated the effectiveness of two oligos (3.32 and 6.64 microM/L) known to have significant activity against the PC-3 prostate cell line in combination therapy with the chemotherapeutic agent paclitaxel (Taxol) (2.5 and 5.0 nm). Therapy was evaluated when oligos and Taxol were administered either as (1) single agents, (2) simultaneously in a combined therapy, or (3) sequentially, a form of combination therapy with both agents being administered in a series. We found that when either of the two oligos were given simultaneously with Taxol, no synergistic activity was noted. However, when sequentially administered in a series 1 d apart, a pretreatment with the antisense directed against TGF-alpha (6.64 microM/L) followed by Taxol (5 nm) had significantly greater activity than these agents similarly administered in the reverse order or simultaneously.>

摘要

相似文献

1
Inhibition of PC-3 prostate cancer cell growth in vitro using both antisense oligonucleotides and taxol.
Med Oncol. 2003;20(1):29-35. doi: 10.1385/MO:20:1:29.
2
Bispecific antisense oligonucleotides with multiple binding sites for the treatment of prostate tumors and their applicability to combination therapy.具有多个结合位点的双特异性反义寡核苷酸用于治疗前列腺肿瘤及其在联合治疗中的适用性。
Methods Find Exp Clin Pharmacol. 2006 Oct;28(8):515-8. doi: 10.1358/mf.2006.28.8.1003571.
3
Synergistic effects of combination therapy employing antisense oligonucleotides with traditional chemotherapeutics in the PC-3 prostate cancer model.
Med Oncol. 2004;21(4):339-48. doi: 10.1385/MO:21:4:339.
4
Treatment of the T98G glioblastoma cell line with antisense oligonucleotides directed toward mRNA encoding transforming growth factor-alpha and the epidermal growth factor receptor.用针对编码转化生长因子-α和表皮生长因子受体的mRNA的反义寡核苷酸处理T98G胶质母细胞瘤细胞系。
Med Oncol. 2001;18(2):121-30. doi: 10.1385/MO:18:2:121.
5
Backbone modification alters the efficacy of antisense oligonucleotides directed against mRNA encoding either TGF-alpha or EGFR in the treatment of prostate cancer cell lines.骨架修饰改变了针对编码转化生长因子α（TGF-α）或表皮生长因子受体（EGFR）的mRNA的反义寡核苷酸在前列腺癌细胞系治疗中的疗效。
Methods Find Exp Clin Pharmacol. 2002 Dec;24(10):649-52. doi: 10.1358/mf.2002.24.10.802313.
6
Multigene targeting of signal transduction pathways for the treatment of breast and prostate tumors: comparison between combination therapies employing bispecific oligonucleotides with either Rapamycin or Paclitaxel.用于治疗乳腺和前列腺肿瘤的信号转导通路多基因靶向：使用双特异性寡核苷酸与雷帕霉素或紫杉醇联合治疗的比较
Med Oncol. 2009;26(2):124-30. doi: 10.1007/s12032-008-9088-5. Epub 2008 Aug 7.
7
Combination chemotherapy employing bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors.采用具有针对自分泌调节生长途径和bcl-2的结合位点的双特异性反义寡核苷酸进行联合化疗以治疗前列腺肿瘤。
Med Oncol. 2007;24(4):372-8. doi: 10.1007/s12032-007-0023-y.
8
Construction of a bispecific antisense oligonucleotide containing multiple binding sites for the treatment of hormone insensitive prostate tumors.构建一种含有多个结合位点的双特异性反义寡核苷酸用于治疗激素不敏感型前列腺肿瘤。
Med Hypotheses. 2005;65(5):905-7. doi: 10.1016/j.mehy.2004.12.032.
9
Bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors.具有针对自分泌调节生长途径和bcl-2的结合位点的双特异性反义寡核苷酸用于治疗前列腺肿瘤。
Med Oncol. 2007;24(2):189-96. doi: 10.1007/BF02698039.
10
siRNA is not more effective than a first generation antisense oligonucleotide when directed against EGFR in the treatment of PC-3 prostate cancer.在治疗PC-3前列腺癌时，当针对表皮生长因子受体（EGFR）时，小干扰RNA（siRNA）并不比第一代反义寡核苷酸更有效。
In Vivo. 2005 Jul-Aug;19(4):653-6.

引用本文的文献

1
Treatment of prostate and breast tumors employing mono- and bi-specific antisense oligonucleotides targeting apoptosis inhibitory proteins clusterin and bcl-2.采用针对凋亡抑制蛋白簇蛋白和 bcl-2 的单链和双链特异性反义寡核苷酸治疗前列腺和乳腺癌肿瘤。
Med Oncol. 2010 Sep;27(3):592-9. doi: 10.1007/s12032-009-9254-4. Epub 2009 Jun 16.
2
Multigene targeting of signal transduction pathways for the treatment of breast and prostate tumors: comparison between combination therapies employing bispecific oligonucleotides with either Rapamycin or Paclitaxel.用于治疗乳腺和前列腺肿瘤的信号转导通路多基因靶向：使用双特异性寡核苷酸与雷帕霉素或紫杉醇联合治疗的比较
Med Oncol. 2009;26(2):124-30. doi: 10.1007/s12032-008-9088-5. Epub 2008 Aug 7.
3

本文引用的文献

1
Antisense therapy: recent advances and relevance to prostate cancer.反义疗法：最新进展及其与前列腺癌的相关性
Clin Prostate Cancer. 2002 Jun;1(1):20-30. doi: 10.3816/cgc.2002.n.003.
2
Backbone modification alters the efficacy of antisense oligonucleotides directed against mRNA encoding either TGF-alpha or EGFR in the treatment of prostate cancer cell lines.骨架修饰改变了针对编码转化生长因子α（TGF-α）或表皮生长因子受体（EGFR）的mRNA的反义寡核苷酸在前列腺癌细胞系治疗中的疗效。
Methods Find Exp Clin Pharmacol. 2002 Dec;24(10):649-52. doi: 10.1358/mf.2002.24.10.802313.
3
GeneBlocs are powerful tools to study and delineate signal transduction processes that regulate cell growth and transformation.
Combination chemotherapy employing bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors.
采用具有针对自分泌调节生长途径和bcl-2的结合位点的双特异性反义寡核苷酸进行联合化疗以治疗前列腺肿瘤。
Med Oncol. 2007;24(4):372-8. doi: 10.1007/s12032-007-0023-y.
4
Bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors.具有针对自分泌调节生长途径和bcl-2的结合位点的双特异性反义寡核苷酸用于治疗前列腺肿瘤。
Med Oncol. 2007;24(2):189-96. doi: 10.1007/BF02698039.
5
Synergistic effects of combination therapy employing antisense oligonucleotides with traditional chemotherapeutics in the PC-3 prostate cancer model.
Med Oncol. 2004;21(4):339-48. doi: 10.1385/MO:21:4:339.
基因模块是研究和描绘调节细胞生长与转化的信号转导过程的强大工具。
Antisense Nucleic Acid Drug Dev. 2002 Jun;12(3):131-43. doi: 10.1089/108729002760220734.
4
Antisense oligonucleotide therapy in urology.泌尿外科中的反义寡核苷酸疗法。
J Urol. 2002 Jul;168(1):239-47.
5
Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides.使用反义Bcl-2寡脱氧核苷酸对前列腺癌进行化学增敏及延迟雄激素非依赖性复发
J Natl Cancer Inst. 2000 Jan 5;92(1):34-41. doi: 10.1093/jnci/92.1.34.
6
Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice.一种C-raf反义寡核苷酸与标准化疗药物联合对皮下移植到裸鼠体内的多种人类肿瘤的抗肿瘤活性。
Clin Cancer Res. 1997 Jul;3(7):1179-85.
7
First "antisense" drug will treat CMV retinitis.
JAMA. 1998 Sep 9;280(10):871.
8
Enhanced expression of bcl-2 following antisense oligonucleotide mediated growth factor deprivation.反义寡核苷酸介导的生长因子剥夺后bcl-2表达增强。
Med Oncol. 1997 Mar;14(1):23-9. doi: 10.1007/BF02990941.
9
Antisense oligonucleotide intralesional therapy for human PC-3 prostate tumors carried in athymic nude mice.
J Surg Oncol. 1996 Jul;62(3):194-200. doi: 10.1002/(SICI)1096-9098(199607)62:3<194::AID-JSO9>3.0.CO;2-2.